Free Technical Research on ImmunoGen and Three More Biotech Equities

Stock Research Monitor: GRFS, HALO, and IMUC

LONDON, UK / ACCESSWIRE / June 22, 2018 / If you want a free Stock Review on IMGN sign up now at www.wallstequities.com/registration. On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Grifols

On Thursday, shares in Barcelona, Spain headquartered Grifols S.A. recorded a trading volume of 2.24 million shares, which was higher than their three months average volume of 703.93 thousand shares. The stock ended at $22.33, declining 2.49% from the last trading session. The Company's shares have gained 9.03% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.62% and 0.74%, respectively. Furthermore, shares of Grifols, which develops, manufactures, and distributes biological medicines on plasma derived proteins in the US, Canada, Spain, rest of the European Union, and internationally, have a Relative Strength Index (RSI) of 46.40.

On June 01st, 2018, research firm Barclays initiated an 'Overweight' rating on the Company's stock. Get the full research report on GRFS for free by clicking below at:

www.wallstequities.com/registration/?symbol=GRFS

Halozyme Therapeutics

San Diego, California headquartered Halozyme Therapeutics Inc.'s stock finished yesterday's session 4.52% lower at $18.59. A total volume of 551,979 shares was traded. The Company's shares have gained 27.42% in the last twelve months. The stock is trading below its 50-day moving average by 2.37%. Furthermore, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes and other drug candidates in the US, Switzerland, and internationally, have an RSI of 47.15. Get access to our top-rated research, including the free report on HALO at:

www.wallstequities.com/registration/?symbol=HALO

ImmunoCellular Therapeutics

At the close of trading on Thursday, shares in Westlake Village, California-based ImmunoCellular Therapeutics Ltd saw a rise of 0.95%, ending the day at $0.27. The stock recorded a trading volume of 244,409 shares. The Company's shares have advanced 1.48% in the previous three months. The stock is trading above its 50-day moving average by 1.59%. Moreover, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of various cancers, have an RSI of 53.76. Click here to subscribe for a free membership which welcomes you with our report on IMUC at:

www.wallstequities.com/registration/?symbol=IMUC

ImmunoGen

Waltham, Massachusetts headquartered ImmunoGen Inc.'s shares ended the day 4.19% higher at $11.68 with a total trading volume of 3.06 million shares, which was above their three months average of 2.79 million shares. The stock has gained 13.29% in the last month and 94.02% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 11.07% and 35.63%, respectively. Additionally, shares of ImmunoGen, which focuses on developing antibody-drug conjugate therapies to treat cancer, have an RSI of 61.29. To get free access to your research report on IMGN, sign up at:

www.wallstequities.com/registration/?symbol=IMGN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities